L'intérêt à découvert pour Accolade donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Accolade. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Accolade (NASDAQ:ACCD) Stock, Rapport sur les intérêts à découvert

Accolade

Accolade Inc offers technology-enabled solutions that help people understand, navigate, and utilize the healthcare system and their workplace benefits. The company's platform combines open, cloud-based intelligent technology with multimodal support from a team of Accolade Care Advocates and clinicians, including registered nurses, physician medical directors, pharmacists, primary care physicians, and other professionals to provide advocacy, medical opinion, and virtual primary care services.

Accolade Inc

This wind down decision will directly affect operations constituting the Longs Business, namely, at the Newcastle and Vereeniging Works, and AMRAS (the rail and structural subsidiary). Newcastle's coke-making operations will continue, though scaled back to reflect reduced demand.&nbsp;

News

Reported Earlier, ArcelorMittal South Africa Reveals Decision To Wind Down Longs Business;  Approximately 3,500 Direct And Indirect Jobs Will Be Affected

Piper Sandler analyst Brent Bracelin maintains Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) with a Overweight and raises the price target from $185 to $208.

Price Target

Analyst Ratings

SNOW

Piper Sandler Maintains Overweight on Snowflake, Raises Price Target to $208

Piper Sandler analyst Brent Bracelin maintains Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) with a Overweight and raises the price target from $470 to $520.

MSFT

Piper Sandler Maintains Overweight on Microsoft, Raises Price Target to $520

Shares of Smart Share Global Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EM#NASDAQ">EM</a>) rose sharply in today's pre-market trading after the company announced the receipt of a preliminary non-binding proposal to <a href="https://www.benzinga.com/quote/EM/earnings">acquire the company</a>.
Smart Share Global shares jumped 44% to $1.04 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Magic Empire Global Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEGL#NASDAQ">MEGL</a>) gained 105.2% to $1.14 in pre-market trading after gaining around 9% on Friday.</li>
<li>Nauticus Robotics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KITT#NASDAQ">KITT</a>) gained 88.4% to $7.15 in pre-market trading after surging 139% on Friday.</li>
<li>Ekso Bionics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKSO#NASDAQ">EKSO</a>) rose 84.9% to $1.35 in pre-market trading after gaining around 17% on Friday.</li>
<li>Simpple Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPPL#NASDAQ">SPPL</a>) rose 70.5% to $2.37 in pre-market trading after surging 31% on Friday.</li>
<li>Microbot Medical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBOT#NASDAQ">MBOT</a>) rose 57% to $3.36 in pre-market trading after climbing around 88% on Friday.</li>
<li>Founder Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGL#NASDAQ">FGL</a>) gained 51% to $2.31 in pre-market trading.</li>
<li>GrafTech International Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAF#NYSE">EAF</a>) gained 38.8% to $2.36 in pre-market trading.</li>
<li>LeddarTech Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LDTC#NASDAQ">LDTC</a>) gained 34.5% to $2.13 in pre-market trading after gaining 23% on Friday.</li>
<li>Richtech Robotics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RR#NASDAQ">RR</a>) gained 31% to $5.36 in pre-market trading following a 70% surge on Friday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Aclarion, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>) fell 35.3% to $0.1930 in pre-market trading. Aclarion gave notice to terminate at-the-market issuance sales agreement with Ascendiant Capital Markets.</li>
<li>AEON Biopharma, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEON#NYSE">AEON</a>) declined 24.4% to $0.43 in pre-market trading after the company announced the launch of proposed public offering.</li>
<li>mF International Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFI#NASDAQ">MFI</a>) fell 21.1% to $1.01 in pre-market trading after jumping around 78% on Friday.</li>
<li>Canterbury Park Holding Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPHC#NASDAQ">CPHC</a>) shares dipped 21.1% to $17.00 in pre-market trading.</li>
<li>BriaCell Therapeutics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCTX#NASDAQ">BCTX</a>) shares fell 18.8% to $0.52 in pre-market trading. BriaCell announced rescheduling of its annual general meeting of shareholders to Feb. 5, 2025.</li>
<li>Where Food Comes From, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WFCF#NASDAQ">WFCF</a>) fell 16.9% to $11.00 in today's pre-market trading.</li>
<li>NSTS Bancorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSTS#NASDAQ">NSTS</a>) fell 16.7% to $10.00 in pre-market trading.</li>
<li>Sunrise New Energy Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EPOW#NASDAQ">EPOW</a>) shares fell 7.4% to $0.8200 in pre-market trading.</li>
<li>Quantum-Si incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSI#NASDAQ">QSI</a>) dipped 7.1% to $3.98 in pre-market trading.</li>
<li>MINISO Group Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNSO#NASDAQ">MNSO</a>) shares tumbled 6.4% to $25.80 in pre-market trading after gaining over 9% on Friday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/01/42791037/delta-air-lines-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">Delta Air Lines Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a></li>
</ul>

Pre-Market Outlook

Markets

Movers

ACON

AEON

BCTX

CPHC

EKSO

Sunrise New Energy Co., Ltd - Ordinary Shares

EPOW

KITT

LDTC

MBOT

MEGL

MNSO

NSTS

SPPL

WFCF

Why Smart Share Global Shares Are Trading Higher By 44%; Here Are 20 Stocks Moving Premarket

Piper Sandler analyst Brent Bracelin maintains Monday.Com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) with a Overweight and lowers the price target from $350 to $345.

MNDY

Piper Sandler Maintains Overweight on Monday.Com, Lowers Price Target to $345

Piper Sandler analyst Brent Bracelin maintains Klaviyo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVYO#NYSE">KVYO</a>) with a Overweight and raises the price target from $45 to $50.

KVYO

Piper Sandler Maintains Overweight on Klaviyo, Raises Price Target to $50

Piper Sandler analyst Brent Bracelin maintains Global E Online (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLBE#NASDAQ">GLBE</a>) with a Overweight and raises the price target from $63 to $66.

GLBE

Piper Sandler Maintains Overweight on Global E Online, Raises Price Target to $66

DHT Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHT#NYSE">DHT</a>) ("DHT" or the "Company") today&nbsp;announced that the Company has purchased 1,481,383 of its own shares in the open market, equivalent to 0.9% of its outstanding shares, at an average price of $8.8899. The shares were purchased during December 2024 and have been retired upon receipt.

Buybacks

DHT Holdings Buys Back Nearly 1.5M Shares in December 2024

The CNN Money Fear and Greed index showed some easing in the overall fear level, while the index remained in the &#8220;Fear&#8221; zone on Friday.
U.S. stocks settled higher on Friday, with the S&amp;P 500 and Nasdaq Composite snapping a five-day losing streak. Tech stocks were among the top performers, with shares of Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) gaining around 4.5% during the session.
On the economic data front, the ISM manufacturing PMI increased by 0.9 points to a reading of 49.3 in December, topping market estimates of 48.4.
All sectors on the S&amp;P 500 closed on a positive note, with consumer discretionary, information technology, and real estate stocks recording the biggest gains on Friday.
The Dow Jones closed higher by around 340 points to 42,732.13 on Friday. The S&amp;P 500 gained 1.26% to 5,942.47, while the Nasdaq Composite climbed 1.77% at 19,621.68 during Friday's session.
Investors are awaiting earnings results from Commercial Metals Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMC#NYSE">CMC</a>) &nbsp;today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 31.7, the index remained in the &#8220;Fear&#8221; zone on Friday, versus a prior reading of 26.7.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/01/42791037/delta-air-lines-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">Delta Air Lines Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a></li>
</ul>
Photo courtesy: Shutterstock

Trading Ideas

NVDA

S&P 500 Snaps Five-Day Losing Streak, Nvidia Surges: Investor Fear Eases, Greed Index Remains In 'Fear' Zone

With U.S. stock futures trading mixed this morning on Monday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects Commercial Metals Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMC#NYSE">CMC</a>) to report quarterly earnings at 81 cents per share on revenue of $1.87 billion before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Commercial Metals shares gained 0.8% to $49.29 in after-hours trading.</li>
<li>FutureFuel Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FF#NYSE">FF</a>) announced it received excise tax registration approval from the IRS. FutureFuel shares gained 5.1% to $5.52 in the after-hours trading session.</li>
<li>Creative Realities, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CREX#NASDAQ">CREX</a>) disclosed that Will Logan has resigned as Chief Financial Officer, effective Jan. 31. Creative Realities shares gained 7.2% to close at $2.68 on Friday.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>The Boeing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) named Dana Deasy as the new chief information digital officer and senior vice president of Information Technology &amp; Data Analytics. Boeing shares gained 0.1% to $170.14 in the after-hours trading session.</li>
<li>Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) announced plans to allocate approximately $80 billion in fiscal 2025 towards the development of data centers aimed at training artificial intelligence (AI) models and deploying AI and cloud-based applications. Microsoft shares gained 0.3% to $424.60 in the after-hours trading session.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/01/42791037/delta-air-lines-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">Delta Air Lines Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a></li>
</ul>
Photo courtesy: Shutterstock

Earnings

CREX

Commercial Metals, Boeing And 3 Stocks To Watch Heading Into Monday

Samsung Electronics Co. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SSNLF#OTC">SSNLF</a>) is gearing up for CES 2025 with major announcements and futuristic tech.
Here&#8217;s everything we know so far.
How to Watch
The global electronics giant will host its press conference on Monday, Jan. 6, at 5:00 PM ET. The conference will stream online.
AI For All: Everyday, Everywhere
Samsung's theme for this year's CES presentation is &#8220;AI for All: Everyday, Everywhere.&#8221; The company plans to showcase how artificial intelligence will improve daily life.
This builds on last year's theme, indicating Samsung's continued focus on AI-driven innovation.
Early announcements from Samsung's newsroom highlight AI-enhanced refrigerators, appliances with built-in screens, and more. Expect features like advanced personalization and smarter home integration.
See Also: <a href="https://www.benzinga.com/25/01/42780776/is-apple-ready-for-a-new-challenge-chinas-smartphone-subsidies-aim-to-boost-domestic-demand-giving-companies-like-huawei-the-upper-hand?itm_source=parsely-api">Apple Rival Huawei, Alibaba, And Others Get Boost As China Doles Out Subsidies To Smartphone Buyers</a>
However, Samsung's CES 2025 showcase won't just be about AI. The company is expected to offer a glimpse of its cutting-edge technologies:
<ul>
<li>Transparent MicroLED Screens: While not yet available in stores, these futuristic displays could steal the spotlight.</li>
<li>Eclipsa 3D Audio: Samsung is partnering with Alphabet Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOF#NASDAQ">GOOF</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google to launch this new technology. It aims to rival Dolby Atmos and DTS.</li>
<li>27-inch QD-OLED Gaming Monitor: Gamers can look forward to enhanced visuals and performance with this new display.</li>
</ul>
Subscribe to the <a href="https://bztechtrends.beehiiv.com/subscribe">Benzinga Tech Trends newsletter</a> to get all the latest tech developments delivered to your inbox.
Will Ballie Finally Arrive
The Ballie robot could make a comeback at CES 2025. This two-time CES veteran has captured imaginations with its potential for home automation and companionship. Many are hoping for a release date or significant advancements in its autonomy, aligning with Samsung's AI theme.
While Samsung will reportedly not reveal the Galaxy S25 smartphone line at CES, the company is expected to hold a separate event later in January.
Check out more of Benzinga's Consumer Tech coverage by <a href="https://www.benzinga.com/topic/consumer-tech">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42780273/samsungs-60-fitbit-killer-galaxy-fit-3-and-200-budget-smartphone-galaxy-a16-5g-are-now-available-in-the-us-what-you-need-to-know?itm_source=parsely-api">Samsung Challenges Google With $60 Fitbit Killer, Also Brings $200 Budget Smartphone To The US: What You Need To Know</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Tech

GOOF

GOOGL

SSNLF

Samsung CES 2025 Press Conference: From Cutting-Edge AI To Transparent Screens, Here's What To Expect

Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) and Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) supplier Foxconn, also known as Hon Hai Technology, posted record revenue in the fourth quarter driven by higher cloud and networking products revenue and strong demand from AI servers.
What Happened: According to the company&#8217;s unaudited monthly revenue report for December, Foxconn&#8217;s fourth-quarter revenue rose 15.17% annually and 15.03% sequentially to a record high of NT$2,132.3 billion or $64.83 billion.
&#8220;Cloud and networking products, computing products, and components and other products showed strong year-on-year growth, while smart consumer electronics remained flattish,&#8221; according to the company.
The cumulative revenue for the full year rose by 11.37% year-on-year to NT$6,859.9 billion or $208.59 billion. Whereas, December&#8217;s monthly revenue rose by 42.31% year-on-year to NT$654.8 billion or $19.9 billion.
Although it was down 2.64% on a monthly basis, as compared to November.
See Also: <a href="https://www.benzinga.com/news/24/03/37848556/nvidias-new-superchip-delivers-8-470-times-the-computing-performance-of-supercomputer-that-jensen-hu">Nvidia's New Superchip Delivers 8,470 Times The Computing Performance Of Supercomputer That Jensen Huang Donated To OpenAI</a>
Why It Matters: Foxconn, renowned for manufacturing Apple products, is capitalizing on the burgeoning artificial intelligence market. The company has entered the server production sector, supplying crucial GB200 chips to Nvidia. To further solidify its position, Foxconn is establishing the world&#8217;s largest manufacturing <a href="https://www.benzinga.com/markets/equities/24/10/41221276/apple-supplier-foxconn-to-build-worlds-largest-nvidia-superchip-factory-amid-soaring-ai-demand">facility</a> for these AI servers in Mexico.
This strategic move aligns with Foxconn&#8217;s vision to leverage the growing AI market. During the company&#8217;s annual tech day in Taipei in October, Chairman Young Liu emphasized Foxconn&#8217;s cutting-edge liquid cooling and heat dissipation technologies, essential for supporting the demanding infrastructure of GB200 servers.
The significance of the company&#8217;s partnership with Nvidia was further highlighted by Benjamin Ting, Foxconn&#8217;s senior vice president for cloud enterprise solutions. At the same event, Ting confirmed the construction of the largest GB200 production facility globally, although he declined to specify the location.
He and Nvidia&#8217;s vice president for AI and robotics, Deepu Talla, jointly emphasized the strong market demand for Nvidia&#8217;s Blackwell platform.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41221276/apple-supplier-foxconn-to-build-worlds-largest-nvidia-superchip-factory-amid-soaring-ai-demand">Apple Supplier Foxconn To Build World&#8217;s Largest Nvidia Superchip Factory Amid Soaring AI Demand</a></li>
</ul>
Photo courtesy: Flickr

Equities

AAPL

Apple Supplier Foxconn Posts Record Revenue, Rides High On AI Server Demand And Nvidia Partnership

Goldman Sachs analyst Kash Rangan initiates coverage on ServiceTitan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTAN#NASDAQ">TTAN</a>) with a Neutral rating and announces Price Target of $100.

Initiation

TTAN

Goldman Sachs Initiates Coverage On ServiceTitan with Neutral Rating, Announces Price Target of $100

Macro Economic Events

Econ #s

Economics

U.K. Services Purchasing Managers Index For December 51.1 Vs. 51.4 Est.; 50.8 Prior

U.K. Composite Purchasing Managers' Index For December 50.4 Vs. 50.5 Est.; 50.5 Prior

Today, Amgen announced that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has granted a conditional marketing authorisation to IMDYLLTRA&#xAE; for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after at least two prior lines of therapy, including platinum-based chemotherapy.1
Small cell lung cancer (SCLC) is an aggressive lung cancer subtype that accounts for approximately 15% of lung cancers.3 ES-SCLC is characterised by rapid tumour growth and metastatic spread.5 Patients with SCLC are often diagnosed after the cancer has reached an advanced stage because symptoms do not typically appear early in the disease.6
"The MHRA's granting of a conditional marketing authorisation for tarlatamab is a significant step forward for people living with small cell lung cancer. More than 34,000 people die from lung cancer in the UK each year.2 There is a vital need for novel treatments, particularly for the extensive stage of small cell lung cancer, where outcomes are especially poor," said Tony Patrikios, Executive Medical Director, Amgen UK &amp; Ireland. "This licence brings us one step closer to offering a new treatment option to eligible patients."
The conditional marketing authorisation is based on results from the Phase 2 open label, multicentre study DeLLphi-301, which evaluated tarlatamab in patients with ES-SCLC who had failed two or more prior lines of treatment.4 Results from the study found that tarlatamab at the 10 mg every two weeks (Q2W) dose (N=99) demonstrated an objective response rate (ORR) of 41% (95% Confidence Interval [CI]: 32 to 52) and a median duration of response (DoR) of 9.7 months (range: 5.9, not estimable [NE]).1

Government

Regulations

AMGN

Amgen's IMDYLLTRA Approved in UK for Advanced Small Cell Lung Cancer Treatment

AerCap Holdings N.V. ("AerCap") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AER#NYSE">AER</a>) has announced its major business transactions during the full year and fourth quarter 2024:
Full Year 2024 Transactions
<ul>
<li>Signed 496 lease agreements, completed 150 purchases and 166 sale transactions.</li>
<li>Signed financing transactions for approximately $17.5 billion.</li>
<li>Repurchased approximately 16.8 million shares, at an average price of $87.80 per share, for a total of approximately $1.5 billion.</li>
</ul>
Fourth Quarter 2024 Transactions
<ul>
<li>Signed 92 lease agreements, including 14 widebody aircraft, 14 narrowbody aircraft, 33 engines and 31 helicopters.</li>
<li>Completed 41 purchases for 27 aircraft (including 4 Airbus A220 Family aircraft, 12 Airbus A320neo Family aircraft, 3 Airbus A330neos, 1 Boeing 737 MAX aircraft, 1 Boeing 787-9 and 6 Embraer E195-E2s for AerCap's owned aircraft portfolio), 10 engines for AerCap's owned engine portfolio and 4 helicopters.</li>
<li>Completed 55 sale transactions for 26 aircraft (including 7 Airbus A320 Family aircraft, 3 Airbus A320neo Family aircraft, 1 Airbus A330, 4 Boeing 737NGs, 1 Boeing 737-800BCF, 1 Boeing 777-300ER and 3 Embraer E190s from AerCap's owned aircraft portfolio and 6 aircraft from AerCap's managed aircraft portfolio), 25 engines (including 16 engines from AerCap's owned engine portfolio and 9 engines from AerCap's managed engine portfolio) and 4 helicopters.</li>
<li>Signed financing transactions for approximately $1.8 billion.</li>
<li>Repurchased approximately 3.1 million shares, at an average price of $94.74 per share, for a total of approximately $297 million.</li>
<li>Paid quarterly cash dividend on ordinary shares of $0.25 per share.</li>
</ul>

AerCap Reports $17.5B in Financing and 496 Lease Deals in 2024, Buys Back $1.5B in Shares

Morgan Stanley analyst Sanjit Singh assumes Palantir Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) with a Underweight rating and announces Price Target of $60.

PLTR

Morgan Stanley Assumes Palantir Technologies at Underweight, Announces Price Target of $60

Portage Biotech, Inc. ("Portage" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, today announced the re-launch of its wholly-owned subsidiary as an independently managed company focused on developing best-in-class adenosine receptor antagonists. Peter Molloy has been appointed Chief Executive Officer of the subsidiary, to be named Cyncado TherapeuticsTM, Inc.
As CEO, Mr. Molloy will lead efforts to secure external financing directly into Cyncado and to advance the clinical development of its portfolio of A2a and A2b receptor antagonists. These therapeutics are distinguished by their potency, selectivity, and optimized binding characteristics, designed to enable robust and sustained inhibition of immune suppression signals in the tumor microenvironment. Developed for dual administration to maximize synergy and achieve a more comprehensive blockade of immune evasion pathways, these therapeutics aim to enhance the immune system's ability to mount a robust anti-tumor response. This approach has the potential to transform immuno-oncology and deliver innovative, well tolerated treatment options for patients.

Management

PRTG

Portage Biotech Spins Off Subsidiary Cyncado Therapeutics to Focus on Cutting-Edge Cancer Treatments, Peter Molloy to Lead Cyncado Therapeutics in Advancing Next-Gen Cancer Treatments

BMO Capital analyst Rufus Hone initiates coverage on Toast (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>) with a Outperform rating and announces Price Target of $45.

TOST

BMO Capital Initiates Coverage On Toast with Outperform Rating, Announces Price Target of $45

Accolade, Inc. 2025 Q2 - Results - Earnings Call Presentation

Accolade, Inc. (ACCD) Q2 2025 Earnings Call Transcript

Barclays analyst Stephanie Davis maintained a Hold rating on Accolade (ACCD – Research Report) today and set a price target of $5.00. Stephanie Dav...

Accolade (ACCD) Maintains Hold Rating Amid Solid Performance and Cautious Market Outlook

Analysts fell to the sidelines weighing in on PTC Therapeutics (PTCT – Research Report) and Accolade (ACCD – Research Report) with neutral ratings,...

Analysts Offer Insights on Healthcare Companies: PTC Therapeutics (PTCT) and Accolade (ACCD)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Accolade (ACCD – Research Report) and Gilead Scien...

Analysts Offer Insights on Healthcare Companies: Accolade (ACCD) and Gilead Sciences (GILD)

Leerink Partners analyst Michael Cherny has reiterated their bullish stance on ACCD stock, giving a Buy rating yesterday. Michael Cherny has given ...

Accolade's Strong Financial Performance and Positive Future Outlook Justify Buy Rating

In a report released yesterday, Stan Berenshteyn from Wells Fargo maintained a Hold rating on Accolade (ACCD – Research Report), with a price targe...

Accolade Financial Analysis: A Hold Rating Amid Revenue Growth Uncertainties and Operational Challenges

Stocks with improving and deteriorating 'TechniGrade' by Piper Sandler

Accolade: A GARP Stock Trading Well Under 1X Revenues

In a report released today, Craig Hettenbach from Morgan Stanley maintained a Hold rating on Accolade (ACCD – Research Report), with a price target...

Morgan Stanley Keeps Their Hold Rating on Accolade (ACCD)

ABCL

ACCD

AMRX

APPF

AVDX

AVGO

BMBL

BOWL

CHGG

DECK

ESTC

FIVN

GILD

HSIC

JNPR

KRMD

MKTX

NBHC

NRIX

OSCR

PTCT

ROKU

RSKD

SDGR

Press Releases

Accolade, Inc. (ACCD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Legal

Accolade To Present at Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase

First-of-its-kind Healthcare Innovation Provides Synchronized, Customized Whole-Health Strategies

Accolade To Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Accolade to Announce Fiscal Second Quarter 2025 Financial Results

Health Care

Accolade Announces Results for Fiscal Second Quarter 2025

Accolade Welcomes Renalogic to Trusted Partner Ecosystem

Accolade To Present at Upcoming Investor Conferences

Accolade to Announce Fiscal Third Quarter 2025 Financial Results

Agilon Health

AirSculpt Technologies, Inc. - Common Stock

AirSculpt Technologies

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

Biodesix

Cryo-Cell International, Inc. Common Stock

Cryo-Cell International

Concord Medical Services Holdings Limited American Depositary Shares (Each represents thirty (30) Class A ordinary shares)

Concord Medical Services

Cross Country Healthcare, Inc. - Common Stock

Cross Country Healthcare

Castle Biosciences

DocGo

Enhabit

Enzo Biochem, Inc. Common Stock ($0.01 Par Value)

Enzo Biochem

Euda Health Holdings Limited - Ordinary Shares

EUDA Health Holdings

Fulgent Genetics

InnovAge Holding

23andMe Holding

ModivCare

National Research Corporation - Common Stock

National Research

Nutex Health

Performant Healthcare, Inc. - Common Stock

Performant Healthcare

P3 Health Partners Inc. - Class A Common Stock

P3 Health Partners

Pennant Gr

Prenetics Global Limited - Class A Ordinary Share

Prenetics Global

SHL Telemedicine Ltd - American Depositary Shares

Comments

Accolade

Intérêt court

Accolade (NASDAQ:ACCD) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL